These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18055476)

  • 21. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
    Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
    J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.
    Tutuncu Z; Kavanaugh A; Zvaifler N; Corr M; Deutsch R; Boyle D
    Arthritis Rheum; 2005 Sep; 52(9):2693-6. PubMed ID: 16142749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
    Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
    Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
    [No Abstract]   [Full Text] [Related]  

  • 30. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis.
    di Minno MN; Peluso R; Iervolino S; Lupoli R; Russolillo A; Scarpa R; di Minno G
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):141-7. PubMed ID: 22514189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
    FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C
    Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
    Mori Y; Kuwahara Y; Chiba S; Itoi E
    Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint tenderness and swelling in biologic-treated inflammatory arthritis patients - a tricky trade off?
    Harty LC; Ng CT; Fearon C; Murray CA; Fitzgerald O; Veale DJ
    Int J Clin Pract; 2012 Feb; 66(2):128-31. PubMed ID: 22257038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.